2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 291

Relation of Foot Pronation during Walking to Risk of Worsening Lateral Patellofemoral and Medial Tibiofemoral Cartilage Damage
Abstract Number: 1980

Relation of Pain Sensitization to the Evolution from Intermittent to Chronic, Persistent Pain in Knee Osteoarthritis: The Multicenter Osteoarthritis Study
Abstract Number: 2345

Relation of Varus Knee Thrust during Walking to Two-Year Incidence of Frequent Ankle, Hip, and Lower Back Pain
Abstract Number: 2943

Relationship Between Menstruation and Symptoms of Behcet’s Syndrome
Abstract Number: 370

Relationship Between Alcohol Consumption and Symptom Severity in Chronic Pain Patients
Abstract Number: 758

Relationship Between Corticosteroids and Adverse Events in SLE –Data from the Clinical Trial Belimumab in Subjects with Systemic Lupus Erythematosus
Abstract Number: 689

Relationship Between Infliximab Serum Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis
Abstract Number: 1572

Relationship Between KDR (VEGFR2) Gene Polymorphisms and Serum KDR Protein Levels in Patients with Rheumatoid Arthritis
Abstract Number: 229

Relationship Between Patient and Disease Factors and Severity of Gout in a Real-World Population
Abstract Number: 140

Relationship Between the Prevalence of Subclinical Tenosynovitis and Therapy in Patients with RA in Clinical Remission: Results from Italian Society of Rheumatology Study Group
Abstract Number: 2028

Relationship of Limb Length Inequality and Incident and Progressive Knee and Hip Radiographic Osteoarthritis and Symptoms
Abstract Number: 3105

Relationships Between a Serum Biomarker of B Cell Differentiation and B Cell Activating Factor Suggest Possible Distinct Pathways of Response to Rituximab in Patients with Systemic Lupus Erythematosus
Abstract Number: 1333

Relevance of Granulomatous Presentation for the Diagnosis and Outcome of Uveitis: Retrospective Case-Control Study of 251 Patients
Abstract Number: 2741

Reliability and Construct Validity of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire – Independent Validation Study in a UK Cohort
Abstract Number: 971

Reliability and Minimal Clinically Important Differences (MCID) of Forced Vital Capacity: Post-Hoc Analyses from the Scleroderma Lung Studies (SLS-I and II)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].